NOVARTIS AG

CIK 1114448 · last filed 2020-07-16

NOVARTIS AG is a corporate insider who has filed 46 SEC Form 4 insider transactions across 14 companies since 2008. The most recent filing, for PSTX, was dated Jul 16, 2020. Across all open-market trades the lifetime net is +$7.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.66B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.66B

Companies

14

Total Filings

46

Lifetime Open-Market Net

$7.62M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Poseida Therapeutics, Inc. (PSTX) Delisted 10%+ Owner 5,908,089 $9.50 $56.13M $0 1 2020-07-16
Akouos, Inc. (AKUS) Delisted 856,262 $13.29 $11.38M $4.25M 1 2020-07-02
GRTX 10%+ Owner 17,448 $17.60 $307.1K -$729.4K 2 2020-06-12
Whitehawk Therapeutics, Inc. (ARPO) Delisted 10%+ Owner 346,207 $33.00 $11.42M -$695.9K 2 2019-04-05
Rein Therapeutics, Inc. (ALRN) Delisted 10%+ Owner 121,739 $2.11 $256.9K $7.47M 6 2018-08-16
ALT 10%+ Owner 186,579 $2.99 $557.9K $0 4 2018-06-15
NTLA 10%+ Owner 4,129,903 $10.89 $44.97M -$45.74M 3 2017-12-14
Ra Pharmaceuticals, Inc. (RARX) Delisted 10%+ Owner 2,307,877 $781.6K 4 2017-06-12
Spyre Therapeutics, Inc. (AGLE) Delisted 10%+ Owner 2,310,924 $12.01 $27.75M $6.00M 1 2016-04-12
KINETA, INC./DE (PTI) Delisted 10%+ Owner 74,940 $6.00M 1 2016-02-17
Eledon Pharmaceuticals, Inc. (TKAI) Delisted 10%+ Owner 502,765 $5.56M 5 2015-07-15
IDENIX PHARMACEUTICALS INC (IDIX) Delisted 33,185,191 $10.23M 9 2011-04-13
Adhera Therapeutics, Inc. (MRNAD) Delisted 10%+ Owner 2,804,670 -$619.8K 3 2011-01-25
ALNY 10%+ Owner 5,602,898 $288.41 $1.62B $15.11M 3 2010-04-26

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-07-16 Poseida Therapeutics, Inc. (PSTX) Delisted Conv (C) +11,816,178 $0 EDGAR
2020-07-02 Akouos, Inc. (AKUS) Delisted Mixed +2,362,516 $4.25M EDGAR
2020-06-12 GRTX Sell (S) −34,464 -$321.6K EDGAR
2020-06-09 GRTX Sell (S) −42,622 -$407.8K EDGAR
2019-04-05 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −261,188 -$258.5K EDGAR
2019-04-02 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −463,526 -$437.4K EDGAR
2018-08-16 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −11,870 -$26.2K EDGAR
2018-08-06 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −9,404 -$31.3K EDGAR
2018-07-31 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −16,916 -$56.7K EDGAR
2018-07-27 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −40,794 -$153.3K EDGAR
Showing 110 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.